Latest Biotech News

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.

BPH Global has transitioned from development to early commercial sales in its Indonesian seaweed operations, securing key offtake agreements and advancing multiple R&D projects. The company also raised $609,000 in fresh capital, positioning itself for growth in sustainable biotech markets.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.